CD8A and non-small cell lung carcinoma: In a recent comparative study between nivolumab-sensitive and nivolumab-resistant NSCLC patients, the latter exhibited a high infiltration of M2-type TAMs and a lower density of CD8+ T and NK cell infiltration in primary tumor tissue [530].